What question did this study set out to answer?

To investigate the role of FcγRIII in platelets' destruction in fetal and neonatal alloimmune thrombocytopenia (FNAIT).

June 12, 2026Blood AdvancesOpen Access

Inhibition of human FcγRIII prevents platelet destruction in a dual-humanized murine model of FNAIT

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial examines FcγRIII blockade to prevent platelet destruction in FNAIT, suggesting potential therapeutic strategy.

To investigate the role of FcγRIII in platelets' destruction in fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Developed a dual-humanized mouse model with HPA-1a-expressing platelets and human FcγRs.
Examined phagocytosis and other mechanisms contributing to platelet clearance in vitro and in vivo.
Used anti-HPA-1a sera and an FcγRIII-blocking antibody to assess platelet destruction dynamics.
Found FcγR-dependent platelet phagocytosis is the key mechanism in platelet destruction with anti-HPA-1a antibodies.
Reduction in platelet clearance observed following FcγRIII blockade in vivo, confirming its central role.
Complement activation and desialylation were occasional findings, but their impact remains unclear.

Tawhidi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark